S. Atalay, “Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study”, Acta Derm Venereol, vol. 100, no. 19, pp. 1–7, Dec. 2020.